Switch theme
Sign up to access all valuation multiples
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
70
LTM Revenue $2.6M
LTM EBITDA -$70.3M
$57.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Orchestra BioMed has a last 12-month revenue of $2.6M and a last 12-month EBITDA of -$70.3M.
In the most recent fiscal year, Orchestra BioMed achieved revenue of $2.6M and an EBITDA of -$64.0M.
Orchestra BioMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Orchestra BioMed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.8M | $2.6M | XXX | XXX | XXX |
| Gross Profit | $3.3M | $2.6M | XXX | XXX | XXX |
| Gross Margin | 120% | 98% | XXX | XXX | XXX |
| EBITDA | -$51.2M | -$64.0M | XXX | XXX | XXX |
| EBITDA Margin | -1856% | -2426% | XXX | XXX | XXX |
| Net Profit | -$33.6M | -$49.1M | XXX | XXX | XXX |
| Net Margin | -1218% | -1862% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Orchestra BioMed's stock price is $3.
Orchestra BioMed has current market cap of $107M, and EV of $57.0M.
See Orchestra BioMed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $57.0M | $107M | XXX | XXX | XXX | XXX | $-1.74 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Orchestra BioMed has market cap of $107M and EV of $57.0M.
Orchestra BioMed's trades at 21.8x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.
Analysts estimate Orchestra BioMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Orchestra BioMed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $57.0M | XXX | XXX | XXX |
| EV/Revenue | 21.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | XXX | XXX |
| P/E | -1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOrchestra BioMed's NTM/LTM revenue growth is 18%
Orchestra BioMed's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $1.0M for the same period.
Over next 12 months, Orchestra BioMed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Orchestra BioMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Orchestra BioMed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2426% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -2407% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $38K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1623% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2530% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Orchestra BioMed acquired XXX companies to date.
Last acquisition by Orchestra BioMed was XXXXXXXX, XXXXX XXXXX XXXXXX . Orchestra BioMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is Orchestra BioMed headquartered? | Orchestra BioMed is headquartered in United States of America. |
| How many employees does Orchestra BioMed have? | As of today, Orchestra BioMed has 70 employees. |
| Who is the CEO of Orchestra BioMed? | Orchestra BioMed's CEO is Mr. David P. Hochman. |
| Is Orchestra BioMed publicy listed? | Yes, Orchestra BioMed is a public company listed on NAS. |
| What is the stock symbol of Orchestra BioMed? | Orchestra BioMed trades under OBIO ticker. |
| When did Orchestra BioMed go public? | Orchestra BioMed went public in 2023. |
| Who are competitors of Orchestra BioMed? | Similar companies to Orchestra BioMed include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Orchestra BioMed? | Orchestra BioMed's current market cap is $107M |
| What is the current revenue of Orchestra BioMed? | Orchestra BioMed's last 12-month revenue is $2.6M. |
| What is the current EBITDA of Orchestra BioMed? | Orchestra BioMed's last 12-month EBITDA is -$70.3M. |
| What is the current EV/Revenue multiple of Orchestra BioMed? | Current revenue multiple of Orchestra BioMed is 21.8x. |
| What is the current EV/EBITDA multiple of Orchestra BioMed? | Current EBITDA multiple of Orchestra BioMed is -0.8x. |
| What is the current revenue growth of Orchestra BioMed? | Orchestra BioMed revenue growth between 2023 and 2024 was -4%. |
| Is Orchestra BioMed profitable? | Yes, Orchestra BioMed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
